secwatch / observer
8-K filed May 28, 2026, 4:05 PM ET ticker VRDN CIK 0001590750
debt confidence high sentiment neutral materiality 0.65

Viridian pre-pays $55.1M Hercules Capital loan, terminates credit facility

Viridian Therapeutics, Inc.\DE

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Viridian Therapeutics, Inc.\DE terminated Loan Agreement with Hercules Capital, Inc. valued at approximately $55.1 million (effective 2026-05-27).

Action
termination
Agreement
credit facility
Counterparty
Hercules Capital, Inc.
Value
approximately $55.1 million
Effective
2026-05-27
Exact text from the filing
On May 27, 2026, Viridian Therapeutics, Inc. (the “Company”) completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to approximately $55.1 million in the aggregate (the “Payoff Amount”), under the Loan and Security Agreement, entered into and effective as of April 1, 2022, by and among the Company, certain of its subsidiaries from time to time party thereto, Hercules Capital, Inc. (“Hercules”) and certain other lenders named therein, which was subsequently amended on August 7, 2023 and October 17, 2025 (as amended, the “Loan Agreement”).
View on SEC.gov

Browse all material agreements →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR
accession 0001193125-26-245186
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.